For the first time to our best knowledge, we demonstrated that the BRAF inhibitor Dabrafenib and the MEK inhibitor Trametinib [8] down-regulate TF in BRAFv600e mutated melanoma cells with a consequent inhibition of the coagulation cascade. The gene discussed is BRAF; the disease is melanoma.